Missed NVDA?
Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
DNLI Stock Forecast 2025-2026
$19.96
Current Price
$2.93B
Market Cap
Buy 18
Hold 0
Sell 0
Wall St Analyst Ratings
Distance to DNLI Price Targets
+100.4%
To High Target of $40.00
+60.3%
To Median Target of $32.00
+20.2%
To Low Target of $24.00
DNLI Price Momentum
+2.5%
1 Week Change
+32.9%
1 Month Change
-19.8%
1 Year Change
-2.1%
Year-to-Date Change
-23.8%
From 52W High of $26.18
+88.8%
From 52W Low of $10.57
📊 TOP ANALYST CALLS
Did DNLI Make This Month's Elite Buy List?
We don't follow just any analyst — only the top 3% with a proven track record make our cut. See if Denali is one of their latest high-conviction picks.
Latest DNLI Stock Price Targets & Analyst Predictions
Based on our analysis of 24 Wall Street analysts, DNLI has a bullish consensus with a median price target of $32.00 (ranging from $24.00 to $40.00). The overall analyst rating is Strong Buy (9.9/10). Currently trading at $19.96, the median forecast implies a 60.3% upside. This outlook is supported by 18 Buy, 0 Hold, and 0 Sell ratings.
The most optimistic forecast comes from Salveen Richter at Goldman Sachs, projecting a 100.4% upside. Conversely, the most conservative target is provided by Jessica Fye at JP Morgan, suggesting a 20.2% upside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
DNLI Analyst Ratings
18
Buy
0
Hold
0
Sell
DNLI Price Target Range
Low
$24.00
Average
$32.00
High
$40.00
Current: $19.96
Latest DNLI Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for DNLI.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Dec 5, 2025 | BTIG | Thomas Shrader | Buy | Reiterates | $32.00 |
| Dec 5, 2025 | Wedbush | Laura Chico | Outperform | Maintains | $31.00 |
| Nov 4, 2025 | JP Morgan | Jessica Fye | Overweight | Maintains | $26.00 |
| Sep 8, 2025 | Cantor Fitzgerald | Josh Schimmer | Overweight | Reiterates | $N/A |
| Aug 18, 2025 | Morgan Stanley | Matthew Harrison | Overweight | Maintains | $30.00 |
| May 19, 2025 | B of A Securities | Tazeen Ahmad | Buy | Maintains | $27.00 |
| May 8, 2025 | Baird | Joel Beatty | Outperform | Maintains | $29.00 |
| May 7, 2025 | HC Wainwright & Co. | Andrew Fein | Buy | Maintains | $32.00 |
| May 7, 2025 | Wedbush | Laura Chico | Outperform | Maintains | $30.00 |
| Mar 10, 2025 | B of A Securities | Tazeen Ahmad | Buy | Maintains | $28.00 |
| Mar 7, 2025 | Morgan Stanley | Matthew Harrison | Overweight | Assumes | $33.00 |
| Mar 5, 2025 | B. Riley Securities | Mayank Mamtani | Buy | Reiterates | $35.00 |
| Mar 3, 2025 | Oppenheimer | Jay Olson | Outperform | Maintains | $42.00 |
| Feb 28, 2025 | HC Wainwright & Co. | Andrew Fein | Buy | Maintains | $87.00 |
| Feb 11, 2025 | Deutsche Bank | David Hoang | Buy | Initiates | $31.00 |
| Jan 28, 2025 | Goldman Sachs | Salveen Richter | Buy | Maintains | $40.00 |
| Jan 7, 2025 | HC Wainwright & Co. | Andrew Fein | Buy | Maintains | $87.00 |
| Jan 7, 2025 | JP Morgan | Jessica Fye | Overweight | Maintains | $24.00 |
| Jan 7, 2025 | Baird | Joel Beatty | Outperform | Initiates | $31.00 |
| Jan 3, 2025 | William Blair | Sarah Schram | Outperform | Initiates | $N/A |
Denali Therapeutics Inc. (DNLI) Competitors
The following stocks are similar to Denali based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
Denali Therapeutics Inc. (DNLI) Financial Data
Denali Therapeutics Inc. has a market capitalization of $2.93B with a P/E ratio of -7.8x. The company generates $0 in trailing twelve-month revenue with a 0.0% profit margin.
Revenue growth is N/A quarter-over-quarter, while maintaining an operating margin of 0.0% and return on equity of -44.4%.
Valuation Metrics
Market Cap
$2.93B
Enterprise Value
$2.12B
P/E Ratio
-7.8x
PEG Ratio
-0.4x
Price/Sales
N/A
Growth & Margins
Revenue Growth (YoY)
N/A
Gross Margin
N/A
Operating Margin
0.0%
Net Margin
0.0%
EPS Growth
N/A
Financial Health
Cash/Price Ratio
+29.0%
Current Ratio
9.8x
Debt/Equity
4.8x
ROE
-44.4%
ROA
-27.3%
💡 SKIP THE NOISE
97% of Analyst Ratings Go Nowhere
We filter thousands of calls to find the few that actually matter. Get the top analyst buy ratings — tracked and updated every Monday and Thursday.
Denali Therapeutics Inc. (DNLI) Business Model
About Denali Therapeutics Inc.
What They Do
Develops therapies for neurodegenerative diseases.
Business Model
Denali Therapeutics generates revenue by developing innovative therapeutic interventions aimed at treating neurodegenerative diseases such as Alzheimer's, Parkinson's, and ALS. The company focuses on engineering therapies that effectively cross the blood-brain barrier, which is crucial for treating central nervous system disorders. It collaborates with research institutions and pharmaceutical companies to advance its product pipeline.
Additional Information
Based in South San Francisco, California, Denali Therapeutics is a key player in the biotechnology industry, addressing significant unmet medical needs and striving to improve the quality of life for patients suffering from neurodegenerative conditions.
Company Information
Sector
Healthcare
Industry
Biotechnology
Employees
517
CEO
Dr. Ryan J. Watts Ph.D.
Country
United States
IPO Year
2017
Website
www.denalitherapeutics.comDenali Therapeutics Inc. (DNLI) Latest News & Analysis
Featured Analysis
Powered by
Zacks Investment Research
Denali Enters Into a $275M Funding Deal With Royalty Pharma
DNLI secures a $275M funding deal with Royalty Pharma tied to potential approvals for its Hunter syndrome therapy.
Dec 05, 2025
By Ekta Bagri
Analyst Blog
Latest News
Quick Summary
Denali Therapeutics Inc. (DNLI) held an Analyst/Investor Day, providing updates on its pipeline and strategic initiatives. Further details on projects and financial outlook were discussed.
Why It Matters
Denali Therapeutics' Analyst/Investor Day may reveal strategic plans, financial forecasts, or pipeline updates, impacting stock valuation and investment decisions.
Source: Seeking Alpha
Market Sentiment:
Neutral
Quick Summary
DNLI has finalized a $275M funding agreement with Royalty Pharma, linked to potential approvals for its therapy aimed at treating Hunter syndrome.
Why It Matters
DNLI's $275M funding boosts its financial position and validates its Hunter syndrome therapy, signaling potential for future revenue and shareholder value increase.
Source: Zacks Investment Research
Market Sentiment:
Neutral
Quick Summary
Denali Therapeutics and Royalty Pharma have entered a $275 million synthetic royalty funding agreement tied to future net sales of tividenofusp alfa.
Why It Matters
The $275 million royalty agreement signals confidence in tividenofusp alfa's market potential, which could enhance Denali's revenue and attract investor interest in both companies.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
Denali Therapeutics (DNLI) is moving to commercial-stage biotech, focusing on its blood-brain barrier platform. It has ~1.5 years of cash runway and a lead candidate, DNL310, with FDA review delayed to April 2026.
Why It Matters
Denali Therapeutics' transition to commercial-stage biotech indicates potential revenue growth. The delayed FDA review may impact timelines, but sufficient cash runway supports upcoming product launches.
Source: Seeking Alpha
Market Sentiment:
Positive
Denali Therapeutics Inc. (DNLI) Presents at Jefferies London Healthcare Conference 2025 Transcript
15 days ago
Quick Summary
Denali Therapeutics Inc. (DNLI) will present at the Jefferies London Healthcare Conference on November 18, 2025, at 7:30 AM EST, featuring CEO Ryan Watts and CFO Alexander Schuth.
Why It Matters
Denali Therapeutics’ participation in a major healthcare conference could signal forthcoming developments or insights, potentially impacting stock performance and investor sentiment.
Source: Seeking Alpha
Market Sentiment:
Neutral
Quick Summary
Denali's Q3 loss has increased year-over-year due to rising expenses, and the FDA has postponed its review of the company's Hunter syndrome therapy to 2026.
Why It Matters
Denali's widening Q3 loss and FDA review delay for its Hunter syndrome therapy signal increased financial risk, potentially impacting stock performance and investor sentiment.
Source: Zacks Investment Research
Market Sentiment:
Negative
Frequently Asked Questions About DNLI Stock
What is Denali Therapeutics Inc.'s (DNLI) stock forecast for 2026?
Based on our analysis of 24 Wall Street analysts, Denali Therapeutics Inc. (DNLI) has a median price target of $32.00. The highest price target is $40.00 and the lowest is $24.00.
Is DNLI stock a good investment in 2026?
According to current analyst ratings, DNLI has 18 Buy ratings, 0 Hold ratings, and 0 Sell ratings. The stock is currently trading at $19.96. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for DNLI stock?
Wall Street analysts predict DNLI stock could reach $32.00 in the next 12 months. This represents a 60.3% increase from the current price of $19.96. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Denali Therapeutics Inc.'s business model?
Denali Therapeutics generates revenue by developing innovative therapeutic interventions aimed at treating neurodegenerative diseases such as Alzheimer's, Parkinson's, and ALS. The company focuses on engineering therapies that effectively cross the blood-brain barrier, which is crucial for treating central nervous system disorders. It collaborates with research institutions and pharmaceutical companies to advance its product pipeline.
What is the highest forecasted price for DNLI Denali Therapeutics Inc.?
The highest price target for DNLI is $40.00 from Salveen Richter at Goldman Sachs, which represents a 100.4% increase from the current price of $19.96.
What is the lowest forecasted price for DNLI Denali Therapeutics Inc.?
The lowest price target for DNLI is $24.00 from Jessica Fye at JP Morgan, which represents a 20.2% increase from the current price of $19.96.
What is the overall DNLI consensus from analysts for Denali Therapeutics Inc.?
The overall analyst consensus for DNLI is bullish. Out of 24 Wall Street analysts, 18 rate it as Buy, 0 as Hold, and 0 as Sell, with a median price target of $32.00.
How accurate are DNLI stock price projections?
Stock price projections, including those for Denali Therapeutics Inc., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: December 7, 2025 3:34 PM UTC